New hope for hard-to-treat cancers: experimental drug targets DLL3

NCT ID NCT04471727

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times

Summary

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancer that has DLL3 protein. The goal is to find the safest dose and see how well the body handles it. About 232 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California, 90048, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02467, United States

  • Karmanos Cancer Center

    Detroit, Michigan, 48201, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10021, United States

  • Providence

    Portland, Oregon, 97213, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of California San Francisco

    San Francisco, California, 94143, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.